✦ LIBER ✦
704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC)
✍ Scribed by E. Raymond; F. Goldwasser; G. Bousquet; C. Le Tourneau; S. Faivre; H. de-Montserrat; P. Stopfer; M. Stefanic; R. Kaiser; J.L. Misset
- Book ID
- 118625345
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 64 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.